Identification of RSPO2/RSPO3 translocations in cancer provides not only an attractive target for Wnt pathway inhibition using antibody approaches but also an intuitive predictive biomarker for RSPO2/RSPO3 antibodies. The gene discussed is RSPO2; the disease is cancer.